L. García Buey-rekin lankidetzan egindako argitalpenak (6)

2019

  1. Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort

    Journal of Viral Hepatitis, Vol. 26, Núm. 1, pp. 55-64

  2. Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain

    PLoS ONE, Vol. 14, Núm. 11

2017

  1. Interferon-related genetic markers of necroinflammatory activity in chronic hepatitis C

    PLoS ONE, Vol. 12, Núm. 7

2015

  1. Perfil clínico y seguimiento de los pacientes con hepatitis C crónica en hospitales españoles: Estudio disHCovery

    Revista Espanola de Quimioterapia, Vol. 28, Núm. 3, pp. 145-153

2013

  1. Polymorphisms in histone deacetylases improve the predictive value of IL-28B for chronic hepatitis C therapy

    Genes and Immunity, Vol. 14, Núm. 5, pp. 317-324

1995

  1. INFORME SOBRE TRATAMIENTO CON INTERFERON EN LAS HEPATITIS CRONICAS

    Gastroenterologia y Hepatologia, Vol. 18, Núm. 1, pp. 33-41